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Background: Severe sepsis is recognized as an inflammatory response causing organ dysfunction in patients with
infection. Antimicrobial therapy is the mainstay of treatment. There is an ongoing demand for local surveillance of
sepsis aetiology and monitoring of empirical treatment recommendations. The present study was established to
describe the characteristics, quality of handling and outcome of patients with severe sepsis admitted to a
Norwegian university hospital.
Methods: A one year prospective, observational study of adult community acquired case-defined severe sepsis was
undertaken. Demographics, focus of infection, microbiological findings, timing and adequacy of empirical antimicrobial
agents were recorded. Clinical diagnostic practice was evaluated. Differences between categorical groups were
analysed with Pearson’s chi-squared test. Predictors of in-hospital mortality were identified in a multivariate
stepwise backward logistic regression model.
Results: In total 220 patients were identified, yielding an estimated annual incidence of 0.5/1000 inhabitants. The
focus of infection was established at admission in 69%. Respiratory tract infection was present in 52%, while
genitourinary, soft tissue and abdominal infections each were found in 12-14%. Microbiological aetiology was
identified in 61%; most prevalent were Streptococcus pneumoniae, Escherichia coli and Staphylococcus aureus.
Independent predictors of in-hospital mortality were malignancy, cardiovascular disease, endocarditis, abdominal
infections, undefined microbiological aetiology, delay in administration of empirical antimicrobial agents ≥ 6 hours and
use of inadequate antimicrobial agents. In patients ≥ 75 years, antimicrobial therapy was less in compliance with current
recommendations and more delayed.
Conclusions: Community acquired severe sepsis is common. Initial clinical aetiology is often revised. Compliance with
recommendations for empirical antimicrobial treatment is lowest in elderly patients. Our results emphasizes that quick
identification of correct source of infection, proper sampling for microbiological analyses, and fast administration of
adequate antimicrobial agents are crucial points in the management of severe sepsis.
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Sepsis is recognized as a dysregulation of the inflamma-
tory response in patients with infection. Progression to
severe forms with organ dysfunction develops in one
out of three patients, commonly resulting in long-term
hospitalization and death [1,2]. Algorithms for identi-
fication and management of severe infection hence
emphasize recordings of vital signs and laboratory data,
aiming at discovering circulatory failure and other organ
dysfunctions at an early stage [3,4]. In recent years, one of
the main focuses in sepsis related research has been on
candidate biomarkers in the host and their possible role
in targeted therapy. However, definite novel therapeutic
approaches have not been established and optimized
anti-infective therapy is still the mainstay of treatment
in severe sepsis. Delayed administration of the initial
dose of antimicrobial agents, the adequacy of antimicro-
bial therapy and, where applicable, delayed surgical
source control, are all independent prognostic factors
[5-8]. Care bundles with guidance on how to diagnose
and handle affected patients, including up-to-date recom-
mendations on empirical treatment, therefore emerges
as one of the most important measures to improve out-
comes in sepsis. In 2007, Llewelyn and Cohen addressed
the relevance of monitoring the microbial epidemiology
of sepsis on a local basis [9]. Based on such knowledge,
empirical recommendations may be customized. Accord-
ingly, we established the present study of adult community
acquired severe sepsis to describe the occurrence, charac-
teristics and handling of affected patients admitted to our
hospital. Secondary objectives were to evaluate our physi-
cians’ compliance with local guidelines and to identify po-
tential predictors of in-hospital mortality in severe sepsis.
Methods
Study setting
Haukeland University Hospital is serving as a local hos-
pital with approximately 350.000 inhabitants in the
catchment area. It is also a tertiary care referral center
in western Norway, with a population of 1.1 million in-
habitants. The current investigation was a one year pro-
spective, case defined observational study of patients
hospitalized in the period from January 1st through
December 2008. Enrollment of patients took place in
the high dependency unit at the Division for infectious
diseases, Department of Medicine, in the general intensive
care unit (ICU) at the Department of Anesthesia and
Intensive care, and in the combined intensive care and
high dependency unit at the Department of Cardiology.
Patient selection
All subjects transferred from the emergency department
(ED) to any of the three units were screened for severe
sepsis according to consensus criteria [3,4]. Patientsolder than 15 years of age hospitalized due to commu-
nity acquired infection, including patients transferred
from affiliated hospitals, were included if they developed
severe sepsis within 24 hours of admission to the primary
institution. Five patients were not recognized within
24 hours, but suspected to have non-infectious con-
ditions. However, they were identified with delay and
included, as their fulfillment of inclusion criteria within
the first 24 hours of hospitalization was documented.
Daily screening in the three units involved were per-
formed. Patients were evaluated for eligibility by use of
admission records, patient charts and inquiries with
senior physicians at the respective wards. All of the
eligible subjects were discussed in consensus meetings
within the group of co-authors before a final decision
of inclusion was made.
Data collection and follow-up
Clinical data were registered prospectively until hospital
discharge or in-hospital death, using predefined case re-
port forms. Information was collected from medical re-
cords, patient charts, and the intensive care electronic
monitoring system IntelliVue Clinical Information
Portfolio (ICIP, Philips Medical Systems, Eindhoven,
the Netherlands). The following parameters were re-
corded at admission; time and date, department affili-
ation, demographics, comorbidities, suspected focus of
infection, heart rate, respiratory rate, blood pressure, body
temperature and Glasgow coma scale (GCS). Laboratory
results were registered continuously. During the follow-
up, data on organ dysfunction and adjunctive sepsis ther-
apies was recorded. Timing and adequacy of antimicrobial
agents was evaluated together with their appropriateness
according to local recommendations. Results from blood
cultures and microbiological analyses of urine, abscess
drainage, sputum, feces and cerebrospinal fluid were col-
lected. Possible contaminants of samples were excluded
from analysis. Antimicrobial susceptibility patterns of
cultured pathogens were registered when available. At
discharge a final diagnosis was established by one con-
sultant (SS), based on retrospective evaluation of all
available records, clinical, microbiological, laboratory
and medical imaging data. Data from medical records
and patient charts was verified before it was entered in
a local database. The main outcome measure was the
in-hospital case fatality rate (CFR). We also calculated
the 28-day all-cause mortality rate. Long-term survival
was assessed after four years.
Calculation of incidence and mortality rate
The population incidence and the 28-day all-cause mor-
tality rate was calculated based on the number of inhabi-
tants > 15 years in the local catchment area in the year
2008. Patients transferred from affiliated hospitals were
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admissions was calculated from total cases in the study.Statistical analyses
Data were analyzed using PASW Statistics 18 software
(SPSS Inc., Chicago, Ill. USA). Differences between cat-
egorical groups were analyzed with Pearson’s chi-squared
test (χ2). To identify predictors of outcome, univariate lo-
gistic regression analyses of factors previously reported to
be associated with mortality was performed. Variables with
P values < .10 were entered into a multivariate stepwise
backward model. Results from the logistic regression ana-
lyses are reported as odds ratios (ORs) with 95% confi-
dence intervals (CIs) from the unadjusted (univariate)
models, the fully adjusted model (step 1 in backward step-
wise regression), and final model (4th and last step in
backward stepwise regression) with p-values from the like-
lihood ratio test. For the latter two models the results of
Hosmer-Lemeshow’s goodness-of-fit-test are reported. All
variables in the logistic regression analyses presented in
table form are categorical. We additionally tested for
linear trend across age groups with 15 years intervals,
with time to administration of the initial antimicrobial
agents assessed as a continuous variable measured in
hours (with exclusion of two extreme outlying values
> 100 hours) and with time assessed as a continuous vari-
able after logarithmic transformation. Long-term survival
was compared across age groups by a Kaplan-Meier plot
with log rank computation results. Overall, two sided P
values < 0.05 were considered significant.Ethical considerations
The study was approved by the Regional Committee for
Medical and Health Research Ethics, Health Region
West (REK-Vest, case number 2010/165).Table 1 Suspected, confirmed and proportion of correct iden
sepsis (n (%))
Infection Suspected at admissiona
Respiratory 101 (45.9)
Genitourinary 25 (11.4)
Soft tissue 23 (10.5)
Abdominal 16 (7.3)
Endocarditis 4 (1.8)
Bacteremia 2 (0.9)
CNS 4 (1.8)
Unknown 36 (16.4)
Not suspected 9 (4.1)
Total 220 (100)
Abbreviations: CNS, central nervous system; n.a., not applicable.
aPercent calculated column-wise, from total cases.
bPercent calculated row-wise, from each infection category’s total number of confirResults
Base-line characteristics
A total of 220 patients with community acquired severe
sepsis were identified, corresponding to an annual in-
cidence of 2.2/1000 hospital admissions and 0.5/1000
inhabitants. Median age was 67 years and there was a
small predominance of male patients (53%). Significant
comorbidity was present in 90%.
Focus of infection
A final clinical diagnosis was established in all patients
at discharge (Table 1). At admission, the correct primary
focus of infection was identified in 69%. The focus was
considered unidentified in 16%, an incorrect focus was
suggested in 11%, whereas the remaining 4% were not
suspected to have infection at admission.
The level of diagnostic precision differed depending
on the nature of the infection. Respiratory tract infection
(RTI) was e.g. suspected in 101 subjects at admission, of
whom 93 were later confirmed while 8 turned out to
have another focus. Overall, RTI was verified in 115 pa-
tients and among these, 22 cases were missed at admis-
sion. As follows, 81% of actual RTIs were assigned with
a correct diagnosis in the ED. In the less frequent causes
of sepsis the level of precision was lower (Table 1).
Microbiology
Microbiological tests were performed in 212 of 220 pa-
tients. A plausible pathogen was identified in 61% of tested
subjects, with a total of 171 positive tests all together
(Table 2). Gram-positive microbes constituted 57%. Over-
all, Streptococcus pneumoniae was most prevalent, closely
followed by Escherichia coli, Staphylococcus aureus and
alpha hemolytic streptococci. Blood cultures were ob-
tained in 198 cases. Of these, 37% were positive, most
often with E. coli, S. pneumoniae or S. aureus respectively.tified focus of infection in community acquired severe
Confirmed at dischargea Correct at admissionb
115 (52.3) 93 (80.9)
31 (14.1) 20 (64.5)
27 (12.3) 18 (66.7)
26 (11.8) 13 (50)
12 (5.5) 4 (33.3)
5 (2.3) 1 [20]
4 (1.8) 2 (50)
0 (0.0) n.a.
n.a. n.a.
220 (100) 151 (68.6)
med cases.
Table 2 Microbiological aetiology in community acquired severe sepsis (n)
Total Blood Urine Abscess drainage Other
Gram-positivea 90 44 27 25 18
Streptococcus pneumonia 29 14 20b 0 5
Alpha hemolytic streptococci 18 7 0 6 7
Group A/C/G streptococci 13 6 0 9 1
Group B streptococci 2 1 0 1 0
Enterococci 6 3 2 0 2
Staphylococcus aureus 20 11 4 9 3
Staphylococcus caprae 1 1 0 0 0
Aerococcus viridans 1 1 1 0 0
Gram-negativea 55 32 21 8 9
Escherichia coli 27 19 13 3 3
Klebsiella 10 6 5 0 1
Enterobacter 1 1 0 0 0
Proteus 2 0 0 1 1
Other Enterobacteriaceae 5 2 3 1 0
Pseudomonas aeruginosa 2 1 0 1 1
Stenotrophomonas maltophilia 1 0 0 1 0
Neisseriae meningitides 2 2 0 0 0
Haemophilus influenzae 2 1 0 0 1
Haemophilus parainfluenzae 2 0 0 0 2
Unspecified gram negative rods 1 0 0 1 0
Anaerobic bacteria 17 6 0 3 9
Clostridium species 5 2 0 0 3c
Bacteroides species 5 3 0 1 2
Prevotella 4 0 0 2 2
Slackia exigua 1 1 0 0 0
Fusobacterium 1 0 0 0 1
Unspecified gram positive rods 1 0 0 0 1
Other 9 0 0 3 6
Candida species 7 0 0 3 4
Aspergillus species 1 0 0 0 1
Influenzavirus A 1 0 0 0 1
Patients with ≥1 positive test 129 74 40 23 29
Unless otherwise specified, numbers shown are all isolated microorganisms in category.
aAnaerobic species not included.
bPositive antigen tests in all 20 cases (14 cases were detected in antigen tests only).
cDetection of Clostridium difficile toxin A in all cases.
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empirical antimicrobial regimens was observed in two iso-
lates only. Both were ESBL-producing E. coli. Polymicro-
bial infections were found in 19% of test-positive patients,
namely in eight soft tissue infections (STIs), six abdominal
infections, six RTIs (aspiration in all cases) and four geni-
tourinary infections (GUIs). Figure 1 shows the relation-
ship between the focus of infection and the proportion of
patients with confirmed microbiological aetiology. Fifteensubjects received antimicrobial treatment prior to hos-
pitalization. Microbiological samples were obtained from
all of them, yet a plausible pathogen was identified in only
five cases.
Antimicrobial agents
Table 3 outlines the initial choice of empirical antimicro-
bial agents and the physicians’ compliance with the rec-
ommendations for empirical treatment of severe sepsis
Figure 1 Microbiological identification rates in different
infection categories (n). Relationship between focus of infection and
the proportion of patients with confirmed microbiological aetiology.
The most prevalent microbe was in RTI (respiratory tract infection);
Streptococcus pneumoniae (28/43), GUI (genitourinary infection);
Escherichia coli (16/28), STI (soft tissue infection); Group A/C/G
streptococci (10/23), ABD (abdominal infection); Escherichia coli (8/15),
and AIE (acute infectious endocarditis); Staphylococcus aureus (5/12).
Table 3 Choice of empirical antimicrobial regimen according
compliance with recommendations (n/n (%))
Focus of infection with recommended
regimen
Suspected focus at ad
Total cases/Cases wit
Respiratoryb,c 100d/82 (82.0)
penicillin G and ciprofloxacin or
penicillin G and gentamicine,f
Genitourinary 25d/20 (80.0)
ampicillin and gentamicinf
Soft tissue 23/18 (78.3)
penicillin G and clindamycin (+/− gentamicin)
Abdominal 16d/11 (68.8)
ampicillin and gentamicin and metronidazol or
3rd generation cephalosporin and metronidazol or
piperacillin-tazobactam or
meropenem
Endocarditis 4/3 (75.0)
penicillin G and gentamicin or
3rd generation cephalosporin
CNS 4/3 (75.0)
penicillin G and 3rd generation cephalosporin
Unknown/bacteremia 38d/34 (89.5)
penicillin G and gentamicin (+/− metronidazol)e,f
Total 210/171 (81.4)
aCorrect and appropriate regimen according to recommendations for empirical ant
bOne patient with a suspected and later verified respiratory tract infection died bef
cSuspected atypical pneumonia: macrolide or doxycycline is added.
dNumber of correct cases including one patient given meropenem as initial agent (
eIf allergic to penicillin: clindamycin.
fIf gentamicin is contraindicated: 3rd generation cephalosporin monotherapy.
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of infection at admission, the empirical choice of anti-
microbial therapy was correct in 81% of the cases. Com-
pliance with the recommendations was lower when
patients were ≥ 75 years of age (χ2 P = 0.029). When
comparing the initial given agent with the confirmed
focus at discharge, 76% had received empirical treatment
appropriate for their final diagnosis. Susceptibility tests
revealed that in the group with defined microbiological
aetiology (n = 129), 82% had been treated with adequate
antimicrobial therapy from the first dose. Compliance
with the recommendations proved to have been better
when adequate therapy was given, in comparison to
when inadequate therapy was given (83% vs. 44%, χ2 P <
0.001).
Median delay before administration of the initial dose
of antimicrobial therapy was 2.8 hours after hospital ad-
mission. Compared to subjects with RTI, the delay was
highest in abdominal infections (2.5 hours vs. 6.9 hours).
Patients in the latter category had a 4.5 times greater
risk of receiving their initial dose after more than sixto suspected and confirmed focus of infection and
mission
h correct regimena
Confirmed focus at discharge
Total cases/Cases with appropriate regimena
115d/96 (83.5)
30d/24 (80.0)
27d/18 (66.7)
26d/13 (50.0)
12/7 (58.3)
4/4 (100)
5/5 (100)
219/167 (76.3)
imicrobial therapy in Haukeland University Hospital in 2008.
ore antimicrobial therapy was implemented.
n = 4 in total).
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Moreover, patients ≥ 75 years of age had a 2.3 times
greater risk of receiving antimicrobial therapy beyond
six hours compared to younger patients (95% CI 1.2-
4.4, χ2 P = 0.008). Among cases with no suspicion of in-
fection at admission, the delay was 13 – 75 hours.
Outcome
Table 4 shows case fatality rates (CFRs) for subgroups of
patients and predictors of outcome in uni- and multi-
variate logistic regression analyses. High CFRs were seen
in patients with malignancy or cardiovascular disease. In
the multivariate analysis, patients with confirmed endo-
carditis and abdominal infections had a significantly
greater risk of death compared to RTI. Detection of
microbiological aetiology and adequate antimicrobial
treatment increased survival. Mortality was increased
when antimicrobial agents had been given before hos-
pital admission and when time to administration of the
initial in-hospital dose of antimicrobial agents was more
than six hours. There were not significant results in
multivariate analyses with cut-offs below six hours or
when testing for linear trend in mortality according to
hourly increasing delays of antimicrobial agents. When
limiting the latter analysis to patients receiving appropri-
ate empirical therapy (adequate antimicrobial agents in
cases with detection of a plausible pathogen, and correct
empirical antimicrobial agents according to Hospital
guidelines in patients with no detection of a pathogen,
n = 178) there was a small significant impact also in
multivariate analysis (p = 0.001, OR 1.06, 95% CI: 1.02 to
1.09). In univariate analyses, patients with a correctly
identified source of infection at admission and patients
receiving appropriate empirical antimicrobial agents ac-
cording to Hospital guidelines had a higher chance of
survival. However, these findings could not be validated
by multivariate analysis. A tendency towards greater
mortality with increasing age was observed, but was
not statistically significant. Replacing age categories in
Table 4 with trend across age groups provided a similar
non-significant result in multivariate analysis, as did
categorization of patients into two groups on the basis
of age below versus ≥75 years. Total in-hospital CFR in
this study was 25%. The 28-day CFR was 24.5% and the
28-day all-cause mortality rate was 13/100 000 inhabitants
per year. One-year mortality was 34.5%. A Kaplan-Meier
curve on survival is presented in Figure 2.
Discussion
We estimated the annual incidence of community ac-
quired severe sepsis in our hospital to be 2.2/1000 ad-
missions and 0.5/1000 inhabitants. In-hospital mortality
was 25% and the 28-day all-cause mortality rate was 13/
100 000 inhabitants per year.Previous data on the occurrence of sepsis in Norway is
limited to a retrospective study using data from the Nor-
wegian Patient Registry, in which the total incidence of
severe sepsis was calculated to 3.0/1000 admissions and
0.47/1000 inhabitants [10]. In contrast to this study, we
did not include nosocomial sepsis which constitutes ap-
proximately 50% of all cases [5,6,11-14]. During three
months prior to the present study we performed a pro-
spective pilot survey of case-defined sepsis in our ED.
Subsequent comparison with cases identified retrospect-
ively by discharge ICD-10 codes revealed that 50% of all
sepsis-cases were missed when using the retrospective
method alone (Nygård, unpublished results). Thus, the
calculation in our current prospective study probably
represents a more accurate estimation of the Norwegian
incidence of community acquired severe sepsis than previ-
ous results. Previous prospective studies with systematic
inclusion from both ICUs and non-ICUs, reporting details
on the occurrence of severe sepsis, are to our knowledge
limited to a single survey from Spain [15]. They calculated
an annual incidence of 1.0/1000 inhabitants, including
nosocomial cases. Other studies of community acquired
severe sepsis have used different methods for patient in-
clusion, and many do not offer data on incidence or are
not applicable for such purpose [16-22].
The respiratory tract was the most frequent origin of
infection in our patients. This is consistent with results
from other studies [5,11-14,23-25]. We diagnosed ab-
dominal infections less frequently, while GUI and STI
were found more often than in many previous reports
[6,11-13,25-27]. However, studies with inclusion of pa-
tients treated outside ICUs have found a distribution of
diagnoses more similar to ours [15,16,23,28,29]. Patients
with abdominal infections have been shown to have a
high demand for intensive care treatment [11]. There
are in addition more abdominal infections in nosocomial
compared to community acquired sepsis [15,30]. In our
study most patients with this diagnosis were treated in
an ICU, whereas patients with GUI on the contrary
mainly were treated outside ICUs. Moreover, patients
with abdominal infection had a prolonged length of stay
(data not shown). In many studies on sepsis epidemi-
ology, frequencies are estimated on the basis of preva-
lence data from ICUs only. Together, these observations
suggest that distribution of various infections is influ-
enced by study design, e.g. our low occurrence of ab-
dominal infections is likely conditional to inclusion of
patients from outside ICUs.
A likely pathogen has been found in 60-75% of eligible
subjects in other studies on sepsis [5,6,13,19,24,31],
comprising positive blood cultures within the range of
22-37% [5,6,12,19,30-33]. This is comparable to our data.
In line with related observations, we identified more
Gram-positive than Gram-negative bacteria [1,12,24].
Table 4 In-hospital mortality in patients with community acquired severe sepsis at Haukeland University Hospital in
2008
Alla Non-
survivors
Unadjusted
models
Fully adjusted
modelb
Final modelc
Characteristic n n (%) OR 95% CI P value OR 95% CI P value OR 95% CI P value
Gender 0.240
Male 117 33 (28.2) 1.00 Reference
Female 103 22 (21.4) 0.69 (0.37, 1.29)
Age (years) 0.065 0.619
16-30 18 1 (5.6) 1.00 Reference 1.00 Reference
30-45 22 4 (18.2) 3.78 (0.38, 37.28) 0.99 (0.07, 14.18)
45-60 36 8 (22.2) 4.86 (0.56, 42.30) 2.27 (0.19, 26.64)
60-75 68 16 (23.5) 5.23 (0.65, 42.43) 2.88 (0.28, 29.54)
≥75 76 26 (34.2) 8.84 (1.11, 70.18) 3.09 (0.28, 33.54)
Comorbidity
None 23 1 (4.3) 0.12 (0.02, 0.92) 0.005
Hypertension 91 18 (19.8) 0.61 (0.32, 1.17) 0.130
Cardiovascular 107 35 (32.7) 2.26 (1.20, 4.24) 0.010 2.18 (0.85, 5.61) 0.101 3.29 (1.45, 7.48) 0.003
Pulmonary 61 14 (23.0) 0.86 (0.43, 1.72) 0.662
Diabetes 38 9 (23.7) 0.92 (0.40, 2.08) 0.836
Malignancy 31 13 (41.9) 2.53 (1.15, 5.58) 0.025 5.97 (1.96, 18.19) 0.001 5.50 (1.92, 15.78) 0.001
Dementia 17 6 (35.3) 1.71 (0.60, 4.88) 0.324
Psychiatric 51 9 (17.6) 0.57 (0.26, 1.27) 0.155
Substance abuse 31 6 (19.4) 0.69 (0.27, 1.77) 0.423
Otherd 74 27 (36.5) 2.42 (1.29, 4.53) 0.006 2.52 (1.11, 5.70) 0.025 2.43 (1.10, 5.35) 0.026
Correct suspected focus of infection 0.020 0.606
Yes 152 31 (20.4) 1.00 Reference 1.00 Reference
No 68 24 (35.3) 2.13 (1.13, 4.02) 0.79 (0.33, 1.91)
Confirmed focus of infection 0.007 0.003 0.001
Respiratory 115 25 (21.7) 1.00 Reference 1.00 Reference
Genitourinary 31 4 (12.9) 0.53 (0.17, 1.67) 0.41 (0.08, 2.21) 0.47 (0.09, 2.39)
Soft tissue 27 6 (22.2) 1.03 (0.38, 2.82) 2.04 (0.55, 7.60) 2.42 (0.68, 8.68)
Abdominal 26 12 (46.2) 3.09 (1.27, 7.51) 2.95 (0.87, 10.03) 3.54 (1.09, 11.43)
Endocarditis 12 7 (58.3) 5.04 (1.47, 17.25) 17.43 (2.74, 111.06) 18.94 (3.45, 104.06)
Bacteremia 5 0 (0.0) 0.00 (0.00, ) 0.00 (0.00, ) 0.00 (0.00, )
CNS 4 1 (25.0) 1.20 (0.12, 12.04) 9.22 (0.71, 118.97) 7.66 (0.63, 93.73)
Microbiological samples 0.008 0.028 0.025
Positive 129 24 (18.6) 1.00 Reference 1.00 Reference 1.00 Reference
Negative 83 26 (31.3) 2.00 (1.05, 3.79) 3.58 (1.34, 9.55) 3.34 (1.29, 8.63)
Not obtained 8 5 (62.5) 7.29 (1.63, 32.63) 2.91 (0.35, 24.09) 4.44 (0.60, 32.95)
Empirical antimicrobial agents
Suspected focus of infection 0.433
Appropriate compliance 171 38 (22.2) 1.00 Reference
Inappropriate compliance 39 11 (28.2) 1.38 (0.63, 3.02)
Confirmed focus of infection 0.027 0.241
Appropriate 168 35 (21.0) 1.00 Reference 1.00 Reference
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Table 4 In-hospital mortality in patients with community acquired severe sepsis at Haukeland University Hospital in
2008 (Continued)
Inappropriate 52 19 (36.5) 2.17 (1.10, 4.27) 0.79 (0.33, 1.91)
Microbiological aetiologye < 0.001
Adequate 106 12 (11.3) 1.00 Reference
Inadequate 23 12 (52.2) 8.55 (3.10, 23.58)
In-hospital initial dose administered 0.002 0.051 0.046
<6 hours after admission 157 30 (19.1) 1.00 Reference 1.00 Reference 1.00 Reference
≥6 hours after admission 54 22 (40.7) 2.91 (1.49, 5.71) 2.52 (1.00, 6.38) 2.48 (1.02, 6.02)
Pre-hospital administration 0.059 0.055 0.041
No 205 48 (23.4) 1.00 Reference 1.00 Reference 1.00 Reference
Yes 15 7 (46.7) 2.86 (0.99, 8.30) 4.13 (0.99, 17.21) 4.20 (1.08, 16.39)
Abbreviations: OR: odds ratio; CI: confidence interval.
an = 220.
bIncludes all categories with P < 0.10 in the unadjusted analyses; n = 211; Hosmer-Lemeshow’s chi-square = 12.38, df = 8, P = 0.135.
cFrom backward stepwise selection at significance level 0.05; n = 211; Hosmer-Lemeshow’s chi-square = 3.18, df = 8, P = 0.923.
dIncluding chronic kidney, liver and rheumatic diseases.
eNot included in multivariate analysis due to a substantial number of not applicable cases (if included, significant in multivariate analysis).
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of microbiological aetiology. A positive urinary antigen
assay was the only laboratory documentation in 48% of
subjects with S. pneumoniae. This is in accordance with
a prospective report on community acquired pneumo-
nia, where 44% of 171 cases with S. pneumoniae were
diagnosed by urinary antigen detection alone [34]. In
Norway, guidelines for pneumococcal vaccination of
adults ≥ 65 years and pre-defined younger persons at risk
have been established since 1996, but vaccine coverage
has not been satisfactory. However, a pneumococcalFigure 2 Long-term survival after community acquired severe sepsis.
in different age groups. Follow-up was four years after hospital admission f
according to Log rank test results (P = 0.000 in analysis of age group 16–50 vs
four-year mortality was 55.5%.conjugated vaccine has been a part of the routine vac-
cination program for children with nearly completely
coverage since 2006. From this point there has been a
marked decline in the number of cases with invasive
S. pneumoniae, also among adults. Thus, the propor-
tion of patients with severe sepsis originating from this
microbe is probably decreasing.
The proportion of patients with detection of a plausible
pathogen differed among the various origins of infection
in our study. The detection rate was low in RTI and ab-
dominal infection in particular. This is also previouslyKaplan-Meier curve on survival after community acquired severe sepsis
or all 220 patients. Survival in all three groups were significant different
. 50–75 and P = 0.001 in analysis of age group 50–75 vs. ≥75). Overall,
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logical samples had a significant greater risk of death than
patients with positive samples. Although not significant in
all categories, this result is consistent when stratification
of infection categories is performed, supporting that the
increased risk of death in cases with negative samples was
retained throughout our multivariate model. Detection of
a plausible pathogen gives the opportunity to administer
validated adequate antimicrobial treatment. In subjects
with negative microbiological samples, correct antimicro-
bial therapy can be delayed or not provided. An increased
risk of death has been demonstrated in patients with se-
vere infection receiving inadequate antimicrobial therapy
[6,7,35-37]. In many of these studies multiresistant iso-
lates were often encountered. We identified no isolates
of MRSA, MRSE or VRE, and only two cases of ESBL-
producing Gram-negative bacilli (of which one was even
suspected, and treated accordingly, at admission). On
the contrary, S. pneumoniae and E. coli were frequently
identified. The CFRs in these two categories were low;
7 and 18.5% respectively (data not shown). Hence, a
possible contributor to the different risk of death among
patients with positive versus negative microbiological
samples might be our high frequency of microbes with
unproblematic resistance properties. Inability to tailor
treatment with effective antimicrobial agents might also
have influenced outcomes of the patients which re-
ceived pre-hospital antimicrobial agents. In a study by
Garnacho-Montero et al., previous antibiotic therapy
within the last month was independently related to ad-
ministration of inadequate antimicrobial therapy [6].
We were able to demonstrate a correlation between
correct use of empirical antimicrobial agents and suscep-
tibility in detected pathogens. It is therefore of concern
that one in five patients did not receive the recom-
mended regimen. One possible explanation for this is
that sepsis is diagnosed on the basis of unspecific cri-
teria, independent of primary focus, microbiological aeti-
ology and host factors. Current diagnostic algorithms
focus on identifying complications of an infection ra-
ther than its aetiology. The level of precision in estab-
lishing the focus of infection was variable and often low
in our study. Only 17 of 38 patients with confirmed ab-
dominal infection or endocarditis were assigned with
the correct focus, and half of them received initial
treatment as recommended. The longest delays before
initiation of antimicrobial therapy were found in these
two groups, and their hospital mortality was high. An
evaluation of the quality of clinical diagnostic practice
in severe sepsis, comparing the suspected focus at
admission with a confirmed diagnosis at discharge, has
to our knowledge not been published previously. We
identified severe sepsis in nine subjects not suspected
with infection at admission. Opposite, a study of theaetiology of illness in suspected severe sepsis found that
18% of the patients had noninfectious diagnoses mim-
icking sepsis [20]. Seen together these observations
suggest a two-sided limitation in commonly used sepsis
algorithms.
We found that a six hour delay or more in administra-
tion of the initial dose of antimicrobial treatment was as-
sociated with an increased risk of death, but could not
demonstrate independent impact on mortality during
the preceding hours, as reported by Kumar et al. in a
study of patients with septic shock [5]. Other studies
investigating the impact of early administration of anti-
microbial therapy have also failed to demonstrate an
hourly decrease in survival [36,38]. Some have demon-
strated beneficial effects on survival with administration
of antimicrobial therapy within the first hour [36,39].
Kumar et al. limited their inclusion to cases given effect-
ive antimicrobial therapy. Likewise, the beneficial effect
found by Gaieski et al. was significant only when anti-
microbial therapy was considered appropriate [36]. Ana-
lyses of our data with the same limitations as Kumar
and Gaieski resulted in significant impact of hourly in-
creasing time to administration of antimicrobial agents
on mortality in multivariate analysis. However, the
hourly effect was low. Since we have included a broad
selection of the population with severe sepsis, ranging
from septic shock to cases with other and less severe
organ dysfunctions, our results concerning timing is in-
evitably influenced by the different levels of severity in
our population. We were not able to severity stratify our
patients and cannot investigate this matter any further.
In patients ≥ 75 years, antimicrobial therapy was less
in compliance with current recommendations and more
delayed. An age dependent risk of in-hospital mortality
has been demonstrated in severe infection [40]. Follow-
ing the results in our study, we question whether this
is solely caused by host factors. Increasing age did not
emerge as an independent risk factor. Subjects ≥ 75 years
had on average one additional comorbidity, a significant
higher presence of cognitive impairment and a signifi-
cant higher creatinine level at admission than younger
patients (data not shown). These data indicates that there
were more potentially complicating factors among elderly
patients. However, our Hospital guidelines are clear in
terms of instructions on adjusting the doses of anti-
microbial agents when needed, as well as recommend-
ing alternative treatment if the primary choice of drug is
contraindicated. This was taken into account when we
evaluated the level of compliance. Hence, we consider
that there is room for improvements in the handling of
our elderly patients, especially given the small difference
in mortality after hospital discharge between patients
aged 50–75 versus ≥75 years during the long-term
follow-up (Figure 2).
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http://www.biomedcentral.com/1471-2334/14/121Strengths and limitations
Major strengths of this study are the prospective design,
inclusion throughout an entire year, a small group of
dedicated investigators and recruitment of patients from
both ICUs and non-ICUs. Major limitations are the sam-
ple size and a lack of severity stratification of the included
patients. Consequently, statistical results are encumbered
with uncertainties. Due to the high number of explanatory
variables included in the logistic regression analysis and
the screening and stepwise selection of variables in the re-
ported results, over fitting is most likely present in the
final model reported. As no formal adjustment for mul-
tiple testing has been performed, most emphasize should
thus be given to the most significant predictors (i.e. with
P < 0.01).
Conclusion
We have found a high incidence of community ac-
quired severe sepsis in a Norwegian university hospital.
Initial clinical aetiology was often revised and the diag-
nosis sometimes overlooked in the emergency department.
Adequate antimicrobial therapy improved outcome, while
undefined microbiological aetiology, endocarditis, ab-
dominal infections and delayed administration of anti-
microbial agents increased the risk of death. A need for
improved handling of elderly patients was identified.
Our results emphasizes that quick identification of cor-
rect source of infection, proper sampling for microbio-
logical analyses, and fast administration of adequate
antimicrobial agents are crucial points in the manage-
ment of severe sepsis.
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